Clinical utility of combined amyloid biomarkers in early cognitive impairment.
While PET refines etiological diagnosis, p-tau217 serves as a robust predictor of amyloid status and cognitive trajectory, and integrating these biomarkers improves risk stratification and may facilitate patient selection for disease-modifying therapies.